Literature DB >> 22710257

Ebola virus antibodies in fruit bats, Ghana, West Africa.

David T S Hayman, Meng Yu, Gary Crameri, Lin-Fa Wang, Richard Suu-Ire, James L N Wood, Andrew A Cunningham.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22710257      PMCID: PMC3376795          DOI: 10.3201/eid1807.111654

Source DB:  PubMed          Journal:  Emerg Infect Dis        ISSN: 1080-6040            Impact factor:   6.883


× No keyword cloud information.
To the Editor: Fruit bats are the presumptive reservoir hosts of Ebola viruses (EBOVs) (genus Ebolavirus, family Filoviridae). When transmitted to humans and nonhuman primates, EBOVs can cause hemorrhagic fevers with high case-fatality rates. In 2008, we detected Zaire EBOV (ZEBOV) antibodies in a single migratory fruit bat (Eidolon helvum) from a roost in Accra, Ghana (). This bat is common in sub-Saharan Africa and lives in large colonies, often in cities. The flight of an individual E. helvum bat during migration has been recorded as >2,500 km (). To understand whether the single seropositive Eidolon helvum bat was evidence of EBOV circulation in the Greater Accra Region or elsewhere in sub-Saharan Africa, we tested serum of 88 nonmigratory fruit bats from the surrounding region of Ghana. Serum samples had been collected, as previously described (,), during May–June 2007 from fruit bats in woodland and tropical forest habitats in southern Ghana within 180 km of Accra. Initial screening for EBOV antibodies was conducted by using ELISA with a 1:1 mixture of recombinant nucleoprotein (NP) of ZEBOV and Reston EBOV (REBOV). Proteins were expressed in an Escherichia coli expression vector with a polyhistadine tag (,). Samples with optical density (OD) readings 3-fold above the mean OD of 2 negative control serum samples were considered EBOV-positive by ELISA. ELISA-positive samples were tested separately (at a dilution of 1:50) for reactivity against ZEBOV and REBOV NPs by using ELISA and Western blot (WB) as described (). Each sample with positive results from both assays was retested at increasing dilutions to determine the highest dilution (endpoint titer) at which it remained positive (>3-fold above the OD for EBOV-negative sera). We detected EBOV antibodies (1:1 mixture of both NP antigens, OD>0.7) in serum samples from 32 of 88 bats (10/27 Epomops franqueti, 14/37 Epomophorus gambianus, 7/16 Hypsignathus monstrosus, 1/4 Nanonycteris veldkampii, and 0/1 Epomops buettikoferi). When tested against an individual NP, 13 of the 32 EBOV-positive serum samples were positive for EBOV (OD >0.50). Of those 13 EBOV-positive samples, 9 were ZEBOV-positive only (from 3 E. franqueti, 4 E. gambianus, and 2 H. monstrosus bats), 3 were REBOV-positive only (from 2 E. gambianus and 1 H. monstrosus bats), and 1 sample from an E. gambianus bat was positive for both ZEBOV and REBOV. Seven samples that the EBOV NP ELISA identified as positive were also positive by WB (Table). Each WB-positive serum sample was positive for the EBOV antigen that it had been most reactive against in the ELISA: 5 WB test results were positive for ZEBOV (2 of those samples also bound to REBOV), and 2 bound to REBOV only. Serum samples with positive OD values at endpoint dilutions >1:50 were definitively positive by WB; whereas those with positive OD values at and endpoint dilution of 1:50 only could be positive, negative, or equivocal by WB (Table).
Table

ZEBOV- and REBOV-specific results of ELISA and Western blot analysis of serum from Ebola virus–positive fruit bats, Ghana*

Location, date, fruit bat speciesSexAgeELISA OD (endpoint titer dilution)

Western blot†
REBOVZEBOVREBOVZEBOV
Sagyimase
May 29, 2007
Epomops franqueti FA0.11 (1:50)0.53 (1:200)+
E. franqueti FSI0.08 (1:50)0.62 (1:100)++
Hypsignathus monstrosus FA0.12 (1:50)1.08 (1:200)++
H. monstrosus FSI1.11 (1:200)0.17 (1:50)+
H. monstrosus FA0.150.71
H. monstrosus‡ MSI0.050.11
May 30, 2007
E. franqueti FA0.1§0.53§+
Adoagyiri
May 31, 2007
Epomophorus gambianus MA0.590.67
E. franqueti§FA0.050.16
E. gambianus FA0.190.55
E. gambianus FA0.13 (1:50)1.24 (1:800)+
E. gambianus FSI0.65 (1:200)0.36 (1:50)+
Oyibi
June 2, 2007
E. gambianus MA0.510.63
Negative control (RAB691/d0)0.190.27
Positive control (RAB691/EBOV-N)1.391.42++

*ZEBOV, Zaire Ebola virus; REBOV, Reston Ebola virus; OD, optical density; A, adult; SI, sexually immature.
†Only serum samples with ZEBOV- or REBOV- positive ELISA results (optical density >0.50) were tested.
‡Negative-control field serum samples.
§Additional serum was not available for endpoint titer dilution determination.

*ZEBOV, Zaire Ebola virus; REBOV, Reston Ebola virus; OD, optical density; A, adult; SI, sexually immature.
†Only serum samples with ZEBOV- or REBOV- positive ELISA results (optical density >0.50) were tested.
‡Negative-control field serum samples.
§Additional serum was not available for endpoint titer dilution determination. Previous serum and viral antigen tests indicated the presence of EBOV among 2 of these bat species (E. franqueti and H. monstrosus) in Gabon, located in central Africa (). Two others (E. gambianus and N. veldkampii) were not previously identified as potential reservoirs. Because these are nonmigratory fruit bats, our findings demonstrate that at least 1 serotype of EBOV circulates in bats in the Upper Guinean forest ecosystem in West Africa. These data might provide evidence that Taï Forest EBOV (TEBOV), formerly known as Côte d’Ivoire EBOV, circulates in this ecosystem among bats native to West Africa (). EBOV antibody titers are highly correlated (), but using TEBOV antigen might increase seroprevalence if TEBOV is the circulating virus. However, geographic location does not necessarily determine EBOV genetic relationships (), and lack of cross-reactivity between serum samples positive for REBOV and ZEBOV in our study might indicate that divergent viruses circulate regionally, given phylogenetic and antigenic relationships between EBOV species (–). We detected a relatively high proportion of EBOV-seropositive fruit bats in a relatively small sample size of mixed species. We suggest that the prevalence of EBOV in these tested bat species is greater than that previously detected in E. helvum bats (1/262 serum samples) (). The higher estimated prevalence in these species occurred despite the fact that E. helvum bats live in large colonies comprising several million animals, which make the species an ideal host for acute RNA virus infections. The relatively low seroprevalence of EBOV among E. helvum bats compared with that among sympatric species is contrary to our findings for a lyssavirus and an uncharacterized henipavirus (,). Our results, therefore, lead us to question what factors (e.g., host, ecologic) limit EBOV circulation in straw-colored fruit bats. Virus isolation is required to characterize EBOVs circulating among fruit bats in Ghana, and additional testing, including longitudinal sampling of bats, is required to further investigate the epidemiology of EBOV in West Africa. Possible public health threats should also be investigated and addressed. These initial findings, however, suggest that the risk for human infection with EBOV might be greater from bat-human contact in rural and forest settings than from urban-roosting E. helvum bats.
  9 in total

1.  Ebola Reston virus infection of pigs: clinical significance and transmission potential.

Authors:  Glenn A Marsh; Jessica Haining; Rachel Robinson; Adam Foord; Manabu Yamada; Jennifer A Barr; Jean Payne; John White; Meng Yu; John Bingham; Pierre E Rollin; Stuart T Nichol; Lin-Fa Wang; Deborah Middleton
Journal:  J Infect Dis       Date:  2011-11       Impact factor: 5.226

2.  Fruit bats as reservoirs of Ebola virus.

Authors:  Eric M Leroy; Brice Kumulungui; Xavier Pourrut; Pierre Rouquet; Alexandre Hassanin; Philippe Yaba; André Délicat; Janusz T Paweska; Jean-Paul Gonzalez; Robert Swanepoel
Journal:  Nature       Date:  2005-12-01       Impact factor: 49.962

3.  ELISA for the detection of antibodies to Ebola viruses.

Authors:  T G Ksiazek; C P West; P E Rollin; P B Jahrling; C J Peters
Journal:  J Infect Dis       Date:  1999-02       Impact factor: 5.226

4.  Long-term survival of an urban fruit bat seropositive for Ebola and Lagos bat viruses.

Authors:  David T S Hayman; Petra Emmerich; Meng Yu; Lin-Fa Wang; Richard Suu-Ire; Anthony R Fooks; Andrew A Cunningham; James L N Wood
Journal:  PLoS One       Date:  2010-08-04       Impact factor: 3.240

5.  Isolation and partial characterisation of a new strain of Ebola virus.

Authors:  B Le Guenno; P Formenty; P Formentry; M Wyers; P Gounon; F Walker; C Boesch
Journal:  Lancet       Date:  1995-05-20       Impact factor: 79.321

6.  Discovery of an ebolavirus-like filovirus in europe.

Authors:  Ana Negredo; Gustavo Palacios; Sonia Vázquez-Morón; Félix González; Hernán Dopazo; Francisca Molero; Javier Juste; Juan Quetglas; Nazir Savji; Maria de la Cruz Martínez; Jesus Enrique Herrera; Manuel Pizarro; Stephen K Hutchison; Juan E Echevarría; W Ian Lipkin; Antonio Tenorio
Journal:  PLoS Pathog       Date:  2011-10-20       Impact factor: 6.823

7.  Antibodies against Lagos bat virus in megachiroptera from West Africa.

Authors:  David T S Hayman; Anthony R Fooks; Daniel Horton; Richard Suu-Ire; Andrew C Breed; Andrew A Cunningham; James L N Wood
Journal:  Emerg Infect Dis       Date:  2008-06       Impact factor: 6.883

8.  Evidence of henipavirus infection in West African fruit bats.

Authors:  David T S Hayman; Richard Suu-Ire; Andrew C Breed; Jennifer A McEachern; Linfa Wang; James L N Wood; Andrew A Cunningham
Journal:  PLoS One       Date:  2008-07-23       Impact factor: 3.240

9.  Newly discovered ebola virus associated with hemorrhagic fever outbreak in Uganda.

Authors:  Jonathan S Towner; Tara K Sealy; Marina L Khristova; César G Albariño; Sean Conlan; Serena A Reeder; Phenix-Lan Quan; W Ian Lipkin; Robert Downing; Jordan W Tappero; Samuel Okware; Julius Lutwama; Barnabas Bakamutumaho; John Kayiwa; James A Comer; Pierre E Rollin; Thomas G Ksiazek; Stuart T Nichol
Journal:  PLoS Pathog       Date:  2008-11-21       Impact factor: 6.823

  9 in total
  48 in total

1.  Ebola, Bats and Evidence-Based Policy : Informing Ebola Policy.

Authors:  James L N Wood; Andrew A Cunningham; Richard D Suu-Ire; Freya L Jephcott; Yaa Ntiamoa-Baidu
Journal:  Ecohealth       Date:  2015-08-05       Impact factor: 3.184

2.  Opinion: Specimen collections should have a much bigger role in infectious disease research and response.

Authors:  Diane DiEuliis; Kirk R Johnson; Stephen S Morse; David E Schindel
Journal:  Proc Natl Acad Sci U S A       Date:  2016-01-05       Impact factor: 11.205

3.  Diverse RNA viruses of arthropod origin in the blood of fruit bats suggest a link between bat and arthropod viromes.

Authors:  Andrew J Bennett; Trenton Bushmaker; Kenneth Cameron; Alain Ondzie; Fabien R Niama; Henri-Joseph Parra; Jean-Vivien Mombouli; Sarah H Olson; Vincent J Munster; Tony L Goldberg
Journal:  Virology       Date:  2018-12-18       Impact factor: 3.616

4.  Biannual birth pulses allow filoviruses to persist in bat populations.

Authors:  David T S Hayman
Journal:  Proc Biol Sci       Date:  2015-03-22       Impact factor: 5.349

5.  Ebola virus disease: history, epidemiology and outbreaks.

Authors:  Jacqueline Weyer; Antoinette Grobbelaar; Lucille Blumberg
Journal:  Curr Infect Dis Rep       Date:  2015-05       Impact factor: 3.725

6.  Serological Evidence for Henipa-like and Filo-like Viruses in Trinidad Bats.

Authors:  Jonathan E Schulz; Stephanie N Seifert; John T Thompson; Victoria Avanzato; Spencer L Sterling; Lianying Yan; Michael C Letko; M Jeremiah Matson; Robert J Fischer; Alexandre Tremeau-Bravard; Janine F R Seetahal; Vernie Ramkissoon; Jerome Foster; Tracey Goldstein; Simon J Anthony; Jonathan H Epstein; Eric D Laing; Christopher C Broder; Christine V F Carrington; Tony Schountz; Vincent J Munster
Journal:  J Infect Dis       Date:  2020-05-11       Impact factor: 5.226

7.  Filoviruses and bats.

Authors:  Amy J Schuh; Brian R Amman; Jonathan S Towner
Journal:  Microbiol Aust       Date:  2017-02-17

8.  Greater migratory propensity in hosts lowers pathogen transmission and impacts.

Authors:  Richard J Hall; Sonia Altizer; Rebecca A Bartel
Journal:  J Anim Ecol       Date:  2014-03-06       Impact factor: 5.091

Review 9.  An update on the use of antibodies against the filoviruses.

Authors:  Erica Ollmann Saphire
Journal:  Immunotherapy       Date:  2013-11       Impact factor: 4.196

10.  Evolutionary history of Ebola virus.

Authors:  Y H Li; S P Chen
Journal:  Epidemiol Infect       Date:  2013-09-16       Impact factor: 4.434

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.